Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation Early Phase 1 Study of ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

NCT06024265 is registered in ClinicalTrials.gov with ExoRNA Bioscience as lead sponsor.

NCT NCT06024265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06024265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation Early Phase 1 Study of ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease
Lead sponsor
ExoRNA Bioscience
Phase
Phase 1
Overall status
Completed
Start date
April 4, 2023
Completion date
September 4, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease